Endometriosis often takes years to diagnose. This ultrasound simulation innovation could help change that
Updated
March 17, 2026 1:01 AM
A group of women facing backwards. PHOTO: UNSPLASH
Endometriosis affects roughly one in ten women worldwide, yet diagnosing the condition often takes years. In many cases, patients experience symptoms for nearly a decade before receiving a confirmed diagnosis. One reason is that detecting endometriosis through ultrasound requires specialized training and clinicians do not always encounter enough real cases to build that expertise.
To address this gap, medical simulation company Surgical Science has introduced a new ultrasound training module designed specifically for identifying endometriosis. The system allows clinicians to practice scanning techniques in a virtual environment, helping them recognize signs of the disease without relying solely on real-patient cases.
A key feature of the simulator is training on the “sliding sign,” an ultrasound indicator used to detect deep endometriosis. Because the condition can appear differently from patient to patient, mastering this assessment in real clinical settings can be difficult. The simulator allows clinicians to repeat the process across multiple scenarios, improving their ability to identify the condition during routine examinations.
The module also incorporates the International Deep Endometriosis Analysis (IDEA) protocol, which provides a structured method for performing a complete pelvic ultrasound assessment. Additional training cases, region-based scenarios and certification options are included to support standardized learning.
Early training results suggest strong improvements in clinician confidence, including higher skill levels in transvaginal ultrasound and better recognition of deep endometriosis. By expanding access to structured ultrasound training, simulation tools like this could help reduce diagnostic delays and improve care for millions of women living with the condition.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.